Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase 2 IZALCO study of subcutaneous isatuximab + car/dex in RRMM finds ORR of 79.7% (N = 74); 74.5% of pts preferred on body injector (OBI) vs. manual injection; no impact of OBI on efficacy, safety, PK, immunogenicity.”
Title: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
Authors: Gurdeep Parmar, Marcelo Capra, Fernanda Seguro, Vania Hungria, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Jiří Minařík, Ivan Špička, Luděk Pour, Herlander Marques, Graça Esteves, Kazutaka Sunami, Junichiro Yuda, Roman Hájek, Jana Mihályová, Christine Soufflet, Disa Yu, Khadija Benlhassan, Victorine Koch, Erin Comerford, Paul Cordero, Florence Suzan, Hang Quach
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
